iShares MSCI Malaysia ETF vs Gilead Sciences, Inc. — how do they compare? iShares MSCI Malaysia ETF trades at $27.97, while Gilead Sciences, Inc. trades at $136.55 (market cap $163.51B). The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while iShares MSCI Malaysia ETF pays none. Which is the better fit depends on your goals.
| EWM | GILD | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $30.42 | $155.80 |
52-Week Low | $23.49 | $108.22 |
Market Cap | — | $163.51B |
Enterprise Value | — | $178.05B |
Dividend Yield | — | 2.49% |
Signals from Pluang's Aura AI — not financial advice
EWM (iShares MSCI Malaysia ETF) trades at $28.005, down 0.3% on the day, with technical indicators showing a bullish bias despite overbought RSI readings. The ETF provides concentrated exposure to Malaysia's financial (54%) and industrial (21%) sectors, benefiting from the country's data center expansion, semiconductor ambitions, and tourism initiatives. Recent news highlights Malaysia's energy diversification efforts amid regional power demand surges.
The outlook remains constructive given Malaysia's structural growth drivers, though investors face currency risk, regional geopolitical tensions, and dependence on global semiconductor demand. Current technical strength suggests near-term upside potential, but elevated RSI levels warrant caution for entry timing.
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Trailing returns across standard periods
Latest headlines on both assets
EWM tracks the MSCI Malaysia Index, providing exposure to the Malaysian equity market. It offers a diversified portfolio of large and mid-sized companies across various sectors in Malaysia.
Read more on EWM →Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →